CDK Inhibitors and FDA: Approved and Orphan

被引：10
作者：
Cicenas, Jonas [1 ,2 ]
Simkus, Jokubas [1 ,3 ]
机构：
[1] MAP Kinase Resource, Bioinformat, Melchior Str 9, CH-3027 Bern, Switzerland
[2] Secondary Sch Varnu Sala, Baltupio G 14, LT-08304 Vilnius, Lithuania
[3] Vilnius Univ, Fac Med, LT-01513 Vilnius, Lithuania
来源：
CANCERS | 2024年 / 16卷 / 08期
关键词：
RIBOCICLIB PLUS FULVESTRANT; POSTMENOPAUSAL WOMEN; CANCER-RESEARCH; BREAST-CANCER; PALBOCICLIB; LETROZOLE; SURVIVAL;
D O I：
10.3390/cancers16081555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 45 条
[1]   Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor [J].
Albert, T. K. ;
Rigault, C. ;
Eickhoff, J. ;
Baumgart, K. ;
Antrecht, C. ;
Klebl, B. ;
Mittler, G. ;
Meisterernst, M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) :55-68
[2]  
[Anonymous], 2017, Cancer Discov, V7, pOF1, DOI 10.1158/2159-8290.CD-NB2017-141
[3]  
[Anonymous], Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy | FDA
[4]   FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J].
Beaver, Julia A. ;
Amiri-Kordestani, Laleh ;
Charlab, Rosane ;
Chen, Wei ;
Palmby, Todd ;
Tilley, Amy ;
Zirkelbach, Jeanne Fourie ;
Yu, Jingyu ;
Liu, Qi ;
Zhao, Liang ;
Crich, Joyce ;
Chen, Xiao Hong ;
Hughes, Minerva ;
Bloomquist, Erik ;
Tang, Shenghui ;
Sridhara, Rajeshwari ;
Kluetz, Paul G. ;
Kim, Geoffrey ;
Ibrahim, Amna ;
Pazdur, Richard ;
Cortazar, Patricia .
CLINICAL CANCER RESEARCH, 2015, 21 (21) :4760-4766
[5]   Oral CDK4/6 inhibitor in clinical trials [J].
Bennet, Neil .
LANCET ONCOLOGY, 2012, 13 (03) :E91-E91
[6]   SGK1 in Cancer: Biomarker and Drug Target [J].
Cicenas, Jonas ;
Meskinyte-Kausiliene, Edita ;
Jukna, Vigilijus ;
Rimkus, Arnas ;
Simkus, Jokubas ;
Soderholm, Diana .
CANCERS, 2022, 14 (10)
[7]   Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020 [J].
Cicenas, Jonas ;
Raciene, Asta .
CANCERS, 2021, 13 (05)
[8]   Kinases and Cancer [J].
Cicenas, Jonas ;
Zalyte, Egle ;
Bairoch, Amos ;
Gaudet, Pascale .
CANCERS, 2018, 10 (03)
[9]   JNK, p38, ERK, and SGK1 Inhibitors in Cancer [J].
Cicenas, Jonas ;
Zalyte, Egle ;
Rimkus, Arnas ;
Dapkus, Dalius ;
Noreika, Remigijus ;
Urbonavicius, Sigitas .
CANCERS, 2018, 10 (01)
[10]   The Aurora kinase inhibitors in cancer research and therapy [J].
Cicenas, Jonas .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (09) :1995-2012
12345